Effect of Matrix Bound Nanovesicles in a rodent model of FSHD: Histomorphologic Analysis
Test period: August 1, 2023 to January 31, 2024
Investigators: George Hussey, PhD and Stephen F. Badylak, DVM, PhD, MD
The proposed studies will evaluate the immune and myogenic cell response following administration of clinical grade MBV (provided by ECM Therapeutics) in a rodent model of FSHD. Given our findings that MBV can mediate receptor-free delivery of protein cargo to immune cells and myoblasts, and potentially orchestrate their function, we will conduct histological and immunolabeling studies to determine if administration of MBV promote an immunomodulatory response towards a constructive M2-like macrophage phenotype, and an increased differentiation of migrating perivascular cells into new muscles fibers accompanied by increased innervation.